Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug

MT Newswires Live

01/21

A joint venture with Keymed Biosciences (HKG:2162) and InnoCare (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.

Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.

Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2505322568"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505322568\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505322568?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505322568","market":"sg","top_or_hot":-1,"title":"Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug","media":"MT Newswires Live","content":"<html><body><p> A joint venture with Keymed Biosciences (HKG:2162) and InnoCare (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.</p><p>Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.</p><p>Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-21 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> A joint venture with Keymed Biosciences (HKG:2162) and InnoCare (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.</p><p>Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.</p><p>Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505322568","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505322568","pubTimestamp":1737459180,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"A joint venture with Keymed Biosciences  and InnoCare  unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","02162":"康诺亚-B","09969":"诺诚健华","BK1583":"高瓴概念"},"translate_title":"康康医疗与诺诚健华合资公司签署抗肿瘤药物商业许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"09969":1,"02162":0.9},"content_text":"A joint venture with Keymed Biosciences (HKG:2162) and InnoCare (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech signed a license agreement with Prolium to develop the CM355 drug for tumors.Under the license deal, Prolium will obtain exclusive rights to develop, register, manufacture, and commercialize the drug outside of Asia, according to a Monday filing with the Hong Kong Exchange.Keymed's Chengdu unit and Innocare Unit Beijing InnoCare will be entitled to upfront and near-term payments of $17.5 million, up to $502.5 million in additional payments, and tiered royalties on net sales from Prolium based on their respective interests in the Beijing Tiannuojiancheng Pharma Tech joint venture.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}